\-\ Texto\\:\\ \ \(0\)\
\-\ esr\\-38\\ \\(0\\-15\\)\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ nasal\\ bx\\-rare\\ granulomas\\ \ \(0\)\
\-\ serum\\ ace\\-\\ 60\\ \\(9\\-67\\)\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ w\\/\\ focal\\ caseation\ \(0\)\
\-\ afb\\ culture\\-\\ no\\ growth\\;\\ smear\\-\\ neg\\.\ \(0\)\
\-\ csf\ \(2\)\
\-\ \\-\\-\\-\ \(165\)\
\-\ hsv\\ dna\\-\\ neg\ \(0\)\
\-\ wnv\\ \\<\\ 1\\-30\ \(0\)\
\-\ fungal\\ culture\\-no\\ growth\\;\\ smear\\-\\ neg\\.\ \(1\)\
\-\ india\\ ink\\-neg\ \(1\)\
\-\ ace\\ \\<3\ \(0\)\
\-\ rbc\\-2\ \(0\)\
\-\ wbc\\-2\\ \ \(0\)\
\-\ protein\\ wnl\ \(0\)\
\-\ mass\\-like\\ meningeal\\ thickening\\ which\\ is\\ t2\\ hypointense\\ and\\ enhances\\ with\\ gadolinium\\.\\ heterogeneous\\ mass\\-like\\ sinus\\ disease\\ with\\ variable\\ enhancement\\.\\ \\ possible\\ communication\\ between\\ the\\ meningeal\\ disease\\ and\\ sinus\\ disease\\ at\\ the\\ area\\ of\\ the\\ cribriform\\ plate\\.\ \(0\)\
\-\ cns\\ sarcoidosis\ \(0\)\
\-\ neurosarcoid\ \(5\)\
\-\ fungal\\ disease\ \(5\)\
\-\ meningiomas\\ with\\ concommitant\\ sinus\\ disease\ \(1\)\
\-\ tb\\ meningitis\ \(0\)\
\-\ wegener\\ granulomatosis\ \(0\)\
\-\ 49y\\/o\\ male\\ with\\ history\\ of\\ sarcoidosis\\ presents\\ with\\ new\\ onset\\ of\\ recurrent\\ seizures\\.\ \(0\)\
\-\ the\\ patient\\'s\\ history\\ of\\ sarcoidosis\\,\\ the\\ nasal\\ biopsy\\ consistent\\ with\\ sarcoid\\,\\ and\\ imaging\\ characteristics\\ all\\ support\\ the\\ diagnosis\\ of\\ neurosarcoid\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ smear\\-\\:\\ 0\\.1277611365792246\ \(0\)\
\-\ neg\\:\\ 0\\.11373911925022583\ \(0\)\
\-\ neurosarcoid\\:\\ 0\\.0959173021250765\ \(0\)\
\-\ mass\\-like\\:\\ 0\\.08670007362188815\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.0839063340514182\ \(0\)\
\-\ meningeal\\:\\ 0\\.07895974773884093\ \(0\)\
\-\ sinus\\:\\ 0\\.06793823847048777\ \(0\)\
\-\ esr\\-38\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ bx\\-rare\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ ace\\-\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ caseation\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ culture\\-\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ dna\\-\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ 1\\-30\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ culture\\-no\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ ink\\-neg\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ rbc\\-2\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ wbc\\-2\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ 49y\\/o\\:\\ 0\\.0638805682896123\ \(0\)\
\-\ nasal\\:\\ 0\\.06131233254052067\ \(0\)\
\-\ fungal\\:\\ 0\\.06003897955803756\ \(0\)\
\-\ wnv\\:\\ 0\\.05885776263338082\ \(0\)\
\-\ cribriform\\:\\ 0\\.05885776263338082\ \(0\)\
\-\ concommitant\\:\\ 0\\.05885776263338082\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.05688651153253253\ \(0\)\
\-\ 9\\-67\\:\\ 0\\.05591960967607528\ \(0\)\
\-\ growth\\:\\ 0\\.053850028929598545\ \(0\)\
\-\ 0\\-15\\:\\ 0\\.05089680401984379\ \(0\)\
\-\ disease\\:\\ 0\\.05060643265274291\ \(0\)\
\-\ india\\:\\ 0\\.04881215132091784\ \(0\)\
\-\ \\<\\:\\ 0\\.047798051123214357\ \(0\)\
\-\ hsv\\:\\ 0\\.04475696445182058\ \(0\)\
\-\ afb\\:\\ 0\\.04335003681094408\ \(0\)\
\-\ ace\\:\\ 0\\.04335003681094408\ \(0\)\
\-\ meningiomas\\:\\ 0\\.04148170993194335\ \(0\)\
\-\ granulomas\\:\\ 0\\.039734158795589086\ \(0\)\
\-\ wegener\\:\\ 0\\.039479873869420465\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.038766540008454864\ \(0\)\
\-\ communication\\:\\ 0\\.03629605749417521\ \(0\)\
\-\ support\\:\\ 0\\.03319863709687854\ \(0\)\
\-\ variable\\:\\ 0\\.03299158367337089\ \(0\)\
\-\ w\\/\\:\\ 0\\.032126752096323305\ \(0\)\
\-\ meningitis\\:\\ 0\\.032126752096323305\ \(0\)\
\-\ protein\\:\\ 0\\.031773200182052055\ \(0\)\
\-\ wnl\\:\\ 0\\.031773200182052055\ \(0\)\
\-\ sarcoid\\:\\ 0\\.031773200182052055\ \(0\)\
\-\ cns\\:\\ 0\\.03168744324258103\ \(0\)\
\-\ plate\\:\\ 0\\.031035644426182913\ \(0\)\
\-\ characteristics\\:\\ 0\\.030805581394917844\ \(0\)\
\-\ serum\\:\\ 0\\.02988529378070547\ \(0\)\
\-\ tb\\:\\ 0\\.029819116363580304\ \(0\)\
\-\ hypointense\\:\\ 0\\.029372061515715524\ \(0\)\
\-\ gadolinium\\:\\ 0\\.029372061515715524\ \(0\)\
\-\ \\;\\:\\ 0\\.029353930267428895\ \(0\)\
\-\ enhances\\:\\ 0\\.02924923862938383\ \(0\)\
\-\ 60\\:\\ 0\\.02701392817923271\ \(0\)\
\-\ seizures\\:\\ 0\\.02662213672075245\ \(0\)\
\-\ recurrent\\:\\ 0\\.026130668631341142\ \(0\)\
\-\ csf\\:\\ 0\\.025858654723231973\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.02276953012170294\ \(0\)\
\-\ biopsy\\:\\ 0\\.021968791606063482\ \(0\)\
\-\ new\\:\\ 0\\.021578173744931584\ \(0\)\
\-\ thickening\\:\\ 0\\.02099003311371994\ \(0\)\
\-\ possible\\:\\ 0\\.02085494361510197\ \(0\)\
\-\ between\\:\\ 0\\.019626779248001765\ \(0\)\
\-\ area\\:\\ 0\\.019578523508219328\ \(0\)\
\-\ onset\\:\\ 0\\.019546530622646014\ \(0\)\
\-\ focal\\:\\ 0\\.017684736261872478\ \(0\)\
\-\ t2\\:\\ 0\\.017526005570654726\ \(0\)\
\-\ all\\:\\ 0\\.01751393832921225\ \(0\)\
\-\ history\\:\\ 0\\.017104558517493963\ \(0\)\
\-\ enhancement\\:\\ 0\\.016597744682050986\ \(0\)\
\-\ consistent\\:\\ 0\\.015183320788631906\ \(0\)\
\-\ imaging\\:\\ 0\\.014507781336634802\ \(0\)\
\-\ 3\\:\\ 0\\.014499822657293765\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01421898065782913\ \(0\)\
\-\ \\'s\\:\\ 0\\.013652511727297428\ \(0\)\
\-\ presents\\:\\ 0\\.012649596344260333\ \(0\)\
\-\ which\\:\\ 0\\.011559018748134411\ \(0\)\
\-\ male\\:\\ 0\\.011197141578894733\ \(0\)\
\-\ \\(\\:\\ 0\\.010469010525273341\ \(0\)\
\-\ \\)\\:\\ 0\\.010341125972656596\ \(0\)\
\-\ at\\:\\ 0\\.00838958806399734\ \(0\)\
\-\ no\\:\\ 0\\.006235102541331899\ \(0\)\
\-\ patient\\:\\ 0\\.006207187905191217\ \(0\)\
\-\ the\\:\\ 0\\.006010838465375035\ \(0\)\
\-\ with\\:\\ 0\\.005087138090864771\ \(0\)\
\-\ of\\:\\ 0\\.004221152202825668\ \(0\)\
\-\ is\\:\\ 0\\.004074570857860331\ \(0\)\
\-\ \\,\\:\\ 0\\.0039233342828592374\ \(0\)\
\-\ and\\:\\ 0\\.003913239255048227\ \(0\)\
\-\ \\.\\:\\ 0\\.00180070110638713\ \(0\)\
